BioCentury
ARTICLE | Politics & Policy

NIH refuses Xtandi march-in request

June 21, 2016 12:38 AM UTC

NIH declined to exercise its march-in rights to allow generic competition for prostate cancer treatment Xtandi enzalutamide from Astellas Pharma Inc. (Tokyo:4503). In a (see BioCentury Extra, Jan. 14).

NIH has previously said price is not a valid justification for use of march-in rights. In March, Burwell declined to have NIH issue guidelines on when the agency may exercise its march-in authority, saying it would do so "on a case by case basis" (see BioCentury Extra, March 8). ...